INSOMNIA: MECHANISMS, HEALTH CONSEQUENCES, AND ADVANCES IN TREATMENT

Tirkashev Nodir Abdurahmon o'g'li
Alfraganus University
Faculty of Medicine, 4th-year student

Abstract: *Insomnia is one of the most common sleep disorders, affecting nearly one-third of the adult population worldwide. It is characterized by difficulty initiating or maintaining sleep, early morning awakenings, and impaired daytime functioning. Chronic insomnia is strongly associated with psychiatric conditions, cardiovascular disease, metabolic disorders, and reduced quality of life. The disorder arises from a combination of hyperarousal, circadian rhythm disruptions, and psychosocial stressors, with underlying genetic and neurobiological factors also contributing. Modern research highlights the role of dysregulated hypothalamic-pituitary-adrenal (HPA) axis activity, altered neurotransmitter signaling, and maladaptive cognitive patterns in perpetuating insomnia.*

Treatment approaches have evolved significantly, with cognitive-behavioral therapy for insomnia (CBT-I) recognized as the gold standard. Pharmacological agents, such as benzodiazepine receptor agonists, melatonin receptor agonists, and dual orexin receptor antagonists, are widely used but require careful management due to side effects and dependency risks. Non-pharmacological strategies, including mindfulness, relaxation techniques, and digital therapeutics, are increasingly employed as complementary options. This article reviews the mechanisms underlying insomnia, its systemic health effects, and recent advances in therapeutic strategies.

Keywords: *Insomnia, sleep disorder, hyperarousal, circadian rhythm, CBT-I, pharmacological therapy, orexin antagonists.*

Insomnia is a pervasive condition with significant personal and public health implications. Unlike transient sleep disturbances that may arise from situational stress, clinical insomnia is defined by persistent difficulty in initiating or maintaining sleep despite adequate opportunity, occurring at least three nights per week for three months or longer. Its prevalence increases with age, comorbid medical conditions, and psychosocial stressors, though it can affect individuals across all demographics.

The disorder is more than a matter of poor sleep—it is a biopsychosocial condition that profoundly impacts cognitive, emotional, and physical health. Patients with insomnia frequently report fatigue, irritability, impaired concentration, and decreased work performance. Furthermore, insomnia is an established risk factor for depression, anxiety, hypertension, obesity, and impaired immune function. The bidirectional

relationship between insomnia and psychiatric conditions complicates treatment, as sleep disturbances both exacerbate and result from mental illness.

Recent advances in neuroscience have improved our understanding of insomnia's pathophysiology. The hyperarousal model suggests that patients with insomnia exhibit elevated sympathetic activity, increased cortisol levels, and altered central nervous system excitability even during sleep. Functional imaging studies demonstrate heightened activity in wake-promoting brain regions, supporting the theory that insomnia reflects a state of persistent physiological activation. Additionally, disruptions in circadian rhythms, maladaptive sleep habits, and genetic predispositions all contribute to the development and chronicity of the disorder.

Insomnia is increasingly recognized as a multidimensional disorder that reflects complex interactions between biological, psychological, and social factors. Its clinical presentation is highly variable, ranging from difficulty falling asleep at the beginning of the night to frequent nocturnal awakenings, early morning awakenings, or a combination of these patterns. Beyond nighttime symptoms, patients often describe a wide array of daytime consequences, including persistent fatigue, decreased alertness, poor concentration, mood disturbances, and impaired occupational or academic performance. The chronic nature of insomnia further contributes to cumulative health risks, making it a major concern for healthcare systems worldwide.

One of the most widely accepted models explaining the persistence of insomnia is the hyperarousal theory. Research indicates that individuals with insomnia exhibit heightened physiological and cognitive arousal both during the day and at night. Polysomnographic studies demonstrate increased high-frequency electroencephalographic activity during sleep, which is associated with intrusive thoughts, rumination, and difficulty disengaging from wakeful states. Biologically, patients with insomnia often show elevated cortisol levels, higher sympathetic nervous system tone, and increased metabolic activity in brain regions such as the thalamus and prefrontal cortex. These findings support the view that insomnia is not merely the absence of sleep but rather the presence of wake-promoting processes that interfere with normal sleep onset and maintenance.

The role of circadian rhythm disruption in insomnia has also been extensively studied. Normally, sleep timing is regulated by the interaction between the homeostatic drive for sleep and the circadian system governed by the suprachiasmatic nucleus of the hypothalamus. Misalignment between internal circadian rhythms and external environmental cues—such as those caused by shift work, jet lag, or irregular sleep schedules—can exacerbate insomnia symptoms. Furthermore, genetic studies suggest that polymorphisms in core circadian clock genes may predispose certain individuals to insomnia, making them more vulnerable to environmental disruptions.

Psychological and behavioral factors play an equally critical role in the development and maintenance of insomnia. Stressful life events are among the most

common precipitants of acute insomnia, while maladaptive coping strategies can prolong the condition into a chronic state. For example, individuals may extend their time in bed in an attempt to increase sleep duration, but this often results in fragmented and less restorative sleep. Similarly, conditioned arousal may occur when the bedroom environment becomes associated with frustration and wakefulness rather than relaxation and sleep. Cognitive factors, such as excessive worry about not sleeping, catastrophic thinking about daytime impairment, and heightened sleep effort, further perpetuate the cycle of insomnia.

The health consequences of chronic insomnia extend far beyond impaired sleep quality. Cardiovascular research has consistently shown associations between insomnia and elevated blood pressure, increased risk of coronary artery disease, and stroke. The mechanisms underlying these associations likely involve chronic sympathetic activation, systemic inflammation, and endothelial dysfunction. Insomnia is also linked to impaired glucose metabolism and insulin resistance, contributing to an increased risk of type 2 diabetes. These findings highlight insomnia as not only a neurological or psychiatric condition but also a systemic disorder with significant cardiometabolic implications.

From a psychiatric perspective, insomnia is strongly comorbid with mood and anxiety disorders. Prospective studies have demonstrated that insomnia is a risk factor for the development of depression, rather than simply a symptom. The bidirectional relationship between sleep and mental health complicates treatment, as poor sleep exacerbates psychiatric symptoms while psychiatric disorders make sleep disturbances more difficult to treat. Moreover, insomnia has been associated with increased risk of suicidal ideation and behavior, underscoring its importance as a target for early intervention.

Cognitive performance and daytime functioning are also profoundly affected by insomnia. Patients often report impaired memory, reduced attention span, and slowed reaction times. These deficits contribute to diminished workplace productivity, increased absenteeism, and higher risk of occupational errors. On a societal level, insomnia-related fatigue and decreased alertness increase the risk of motor vehicle accidents, creating significant public safety concerns. Estimates suggest that insomnia contributes billions of dollars annually in direct healthcare costs and indirect economic losses due to reduced productivity.

Advances in neuroimaging and neurophysiology have provided new insights into the brain mechanisms underlying insomnia. Functional magnetic resonance imaging studies reveal hyperactivation of the amygdala and prefrontal cortex in insomnia patients, particularly in response to emotional stimuli, suggesting a link between sleep disturbances and heightened emotional reactivity. Additionally, alterations in gamma-aminobutyric acid (GABA) neurotransmission, which normally promotes sleep by inhibiting wake-promoting brain regions, have been observed in insomnia patients.

These neurobiological findings not only enhance understanding of the disorder but also open new avenues for targeted treatment development.

In terms of treatment, cognitive-behavioral therapy for insomnia (CBT-I) is widely regarded as the gold standard. This structured, evidence-based intervention typically involves techniques such as stimulus control, sleep restriction, cognitive restructuring, and relaxation training. Numerous randomized controlled trials have demonstrated the efficacy of CBT-I in improving sleep onset latency, total sleep time, and sleep efficiency, with benefits persisting long after treatment completion. Importantly, CBT-I addresses both the behavioral and cognitive components of insomnia, breaking the vicious cycle of conditioned arousal and maladaptive thought patterns.

Pharmacological treatments remain a mainstay in clinical practice, particularly for patients who require rapid relief of symptoms. Benzodiazepine receptor agonists, such as zolpidem and eszopiclone, are effective for short-term use but carry risks of dependence, tolerance, and residual daytime sedation. Melatonin receptor agonists, such as ramelteon, offer an alternative with fewer side effects, particularly for patients with circadian-related sleep disturbances. More recently, dual orexin receptor antagonists (DORAs), such as suvorexant and lemborexant, have been developed to target the orexin system, which plays a central role in wakefulness regulation. Clinical trials suggest that these agents may provide effective and well-tolerated options for long-term management of insomnia.

Complementary and non-pharmacological therapies are also gaining prominence in the management of insomnia. Mindfulness meditation, yoga, and relaxation techniques have shown promise in reducing hyperarousal and improving sleep quality. Light therapy is particularly useful for patients with circadian rhythm-related insomnia, helping realign internal clocks with external light-dark cycles. Furthermore, digital therapeutics, including smartphone-based CBT-I programs, are expanding access to effective treatment for patients who may not have access to specialized sleep clinics. These innovations reflect a growing recognition that insomnia is best addressed through a multimodal and individualized treatment approach.

The integration of lifestyle modifications into insomnia management is equally important. Regular exercise, avoidance of caffeine and alcohol in the evening, maintaining consistent sleep schedules, and optimizing the sleep environment are foundational strategies that enhance the effectiveness of other interventions. Sleep hygiene education, although insufficient as a standalone treatment, provides essential knowledge that empowers patients to adopt healthier sleep practices.

Future directions in insomnia research are increasingly focused on precision medicine approaches. By identifying genetic, neurobiological, and psychological subtypes of insomnia, researchers hope to develop targeted therapies that maximize efficacy while minimizing adverse effects. Advances in wearable technology and digital health monitoring will likely play an important role in personalizing treatment

and tracking outcomes in real time. Moreover, the growing field of chronotherapy, which emphasizes the timing of interventions to align with circadian biology, holds promise for optimizing the effectiveness of both behavioral and pharmacological treatments.

In summary, insomnia is far more than a nuisance of sleepless nights; it is a complex, multifactorial disorder with profound consequences for individual health and societal well-being. Its pathophysiology involves hyperarousal, circadian dysregulation, and maladaptive cognitive-behavioral patterns, while its health impacts span cardiovascular, metabolic, psychiatric, and cognitive domains. Although effective treatments exist, challenges remain in ensuring long-term adherence and accessibility. Continued research and innovation are needed to refine current therapies and develop novel approaches that address the diverse needs of patients suffering from this pervasive disorder.

Insomnia is a widespread and multifactorial sleep disorder with profound implications for physical, cognitive, and psychological health. Chronic insomnia contributes to cardiovascular disease, metabolic dysfunction, psychiatric disorders, cognitive impairments, and reduced quality of life. The disorder arises from a combination of hyperarousal, circadian rhythm disruption, and maladaptive cognitive-behavioral patterns, which perpetuate the cycle of poor sleep.

Cognitive-behavioral therapy for insomnia (CBT-I) remains the gold standard for treatment, offering long-term improvements without the risks associated with pharmacotherapy. Pharmacological interventions, including benzodiazepine receptor agonists, melatonin receptor agonists, and dual orexin receptor antagonists, provide additional therapeutic options when clinically indicated. Non-pharmacological approaches, such as mindfulness, relaxation techniques, light therapy, and digital therapeutics, complement traditional therapies and help address insomnia’s multidimensional nature.

Future research should continue to refine personalized and precision medicine approaches, integrating neurobiological, genetic, and behavioral data to optimize treatment outcomes. Recognizing insomnia as a significant public health concern is essential for promoting early detection, effective intervention, and improved long-term health. Addressing insomnia holistically has the potential to enhance individual well-being, cognitive function, and overall societal productivity.

References

1. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc-Groselj, L., Ellis, J. G., ... & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. *Journal of Sleep Research*, 26(6), 675–700.

2. Morin, C. M., & Benca, R. (2012). Chronic insomnia. *The Lancet*, 379(9821), 1129–1141.

3. Perlis, M. L., Aloia, M. S., & Kuhn, B. (2011). Behavioral treatments for sleep disorders. In M. H. Kryger, T. Roth, & W. C. Dement (Eds.), *Principles and Practice of Sleep Medicine* (5th ed., pp. 795–805). Elsevier Saunders.

4. Baglioni, C., Battagliese, G., Feige, B., Spiegelhalder, K., Nissen, C., Voderholzer, U., ... & Riemann, D. (2011). Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. *Journal of Affective Disorders*, 135(1-3), 10–19.

5. Vgontzas, A. N., & Chrousos, G. P. (2002). Sleep, stress, and disorders of the stress system. *Nature Reviews Endocrinology*, 3(9), 675–685.

6. Winkelman, J. W. (2008). Clinical and polysomnographic features of primary insomnia. *Journal of Clinical Sleep Medicine*, 4(5), 487–496.

7. Riemann, D., Spiegelhalder, K., Feige, B., Voderholzer, U., Berger, M., & Perlis, M. (2010). The hyperarousal model of insomnia: A review of the concept and its evidence. *Sleep Medicine Reviews*, 14(1), 19–31.

8. Buysse, D. J., Germain, A., Hall, M., Monk, T. H., & Nofzinger, E. (2011). A neurobiological model of insomnia. *Drug Discovery Today: Disease Models*, 8(4), 129–137.

9. Morin, C. M., Bootzin, R. R., Buysse, D. J., Edinger, J. D., Espie, C. A., & Lichstein, K. L. (2006). Psychological and behavioral treatment of insomnia: Update of the recent evidence (1998–2004). *Sleep*, 29(11), 1398–1414.

10. Krystal, A. D. (2012). Insomnia in women. *Clinical Cornerstone*, 14(3), 33–44.